CAH CARDINAL HEALTH INC
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 721371 · Fiscal year ends 06/30
Financial factors as of 2026-06-30 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY14.2%
TTM net income YoY9.8%
TTM EPS YoY12.1%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR73.2%
Margins
Gross margin3.8%
Operating margin1.0%
Net margin0.7%
FCF margin1.8%
EBITDA margin1.4%
Returns
ROE—
ROA3.1%
ROIC (approx.)135.8%
Asset turnover4.61x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio0.88x
Interest coverage7.51x
Cash quality & payout
Operating cash flow / net income3.02x
Accruals ratio-6.3%
Payout ratio28.6%
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $254.25B | $222.58B |
| Cost of revenue | $244.47B | $214.41B |
| Gross profit | $9.77B | $8.17B |
| SG&A expense | $6.13B | $5.38B |
| Operating income | $2.61B | $2.27B |
| Interest expense | $348.00M | $215.00M |
| Pretax income | $2.17B | $2.10B |
| Income tax | $469.00M | $532.00M |
| Net income | $1.71B | $1.56B |
| EBITDA | $3.57B | $3.06B |
| EPS (basic) | 7.27 | 6.48 |
| EPS (diluted) | 7.23 | 6.45 |
| Dividends declared per share | 2.04 | 2.02 |
| Weighted avg. shares (diluted) | 237.00M | 242.00M |
| Balance sheet | ||
| Cash & equivalents | $4.86B | $3.87B |
| Receivables | $13.81B | $13.24B |
| Inventory | $17.30B | $16.83B |
| Current assets | $38.75B | $36.37B |
| PP&E, net | $3.03B | $2.86B |
| Goodwill | $11.44B | $9.69B |
| Intangibles | $2.19B | $2.49B |
| Total assets | $57.30B | $53.12B |
| Current liabilities | $43.90B | $38.90B |
| Short-term debt | $1.88B | $550.00M |
| Long-term debt | $7.00B | $7.98B |
| Total debt | $8.89B | $8.53B |
| Total liabilities | $60.02B | $55.76B |
| Shareholders' equity | -$2.88B | -$2.78B |
| Net debt | $4.03B | $4.65B |
| Cash flow statement | ||
| Operating cash flow | $5.17B | $2.40B |
| Capital expenditure | $649.00M | $547.00M |
| Free cash flow | $4.53B | $1.85B |
| Investing cash flow | -$2.58B | -$5.59B |
| Financing cash flow | -$1.60B | $1.94B |
| Depreciation & amortization | $956.00M | $790.00M |
| Stock-based compensation | $367.00M | $244.00M |
| Dividends paid | $491.00M | $494.00M |
| Share buybacks | $1.36B | $765.00M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.